Navigation Links
GeoVax Labs, Inc. Announces First Quarter Financial Results
Date:5/7/2009

ATLANTA, May 7 /PRNewswire-FirstCall/ --GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biotechnology company focused on development of an HIV/AIDS vaccine, today announced its financial results for the three months ended March 31, 2009.

GeoVax reported a net loss of $861,509 for the three months ended March 31, 2009, compared to $682,510 for the same period in 2008. Net losses were partially offset by grant revenues of $710,155 and $599,991 for each period, respectively, related to the Company's grant from the National Institutes of Health in support of its HIV/AIDS vaccine development activities. As of March 31, 2009, the Company reported cash balances totaling $1,970,971.

Summarized financial information is attached. Further information concerning the Company's financial position and results of operations are included in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission.

Management Commentary

Robert McNally, GeoVax's President & CEO, commented, "We are pleased with our first quarter financial results, as we continue to hold the line on our operational expenses and maintain a steady cash balance position. We are also pleased with our Phase 2a preventative AIDS human trial commencement of injections in February and are looking forward to our human therapeutic trial launch later this year."

Dr. McNally continued, "Despite the global financial crisis, we anticipate our financial position to remain steady during the year, thanks to the National Institutes of Health's (NIH) National Institutes of Allergy and Infectious Diseases (NIAID) direct grant to GeoVax towards the research and development of our vaccines program; human clinical trials support and financial assistance received from NIH-NIAID through the HIV Trials Network; and our planned use of funding provided by the common stock purchase agreement with Fusion Capital
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
9. GeoVax to Present at the BIO CEO & Investor Conference 2009
10. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
11. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Rock Hill, SC (PRWEB) October 22, 2014 ... the expansion of its cardiovascular pharmacogenetics menu, which ... improved patient outcomes. With PCLS’s evidence-based results, ... individual needs and optimize their therapy, while minimizing ... , In the U.S., according to the FDA ...
(Date:10/22/2014)... 22, 2014 Nuvilex, Inc. (OTCQB: NVLX) – ... people worldwide are living with diabetes, with  that number ... The global market for diabetes treatments is approximately $500 ... worldwide died from pancreatic cancer.  Pancreatic cancer is the ... in the United States , and ...
(Date:10/20/2014)... Mapp Biopharmaceutical,s valiant effort to produce ... fight the Ebola outbreak will make the public ... of pharmaceuticals can be, according to Kalorama Information.  ... some may be taken aback by the three-month ... knowledge are well aware of the complex issues ...
(Date:10/20/2014)... , October 20, 2014 , ... (GI) disorders and the delivery of care has revealed ... and worrying inequalities in the provision of healthcare services ... was commissioned by United European Gastroenterology (UEG), have been ... and public awareness of the burden of GI disorders ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5
... Milwaukee, Wis. - In a move designed ... Gov. Jim Doyle has announced a partnership agreement with ... companies that conduct stem cell research at non-profit and ... under the stem cell patents held by WARF. , ...
... Wis. - The Center for International Blood and ... Wisconsin has won a contract worth $6,180,029 to collect ... cell transplants that use cells from bone marrow or cord ... part of the U.S. Department of Health and Human ...
... This week, the clock starts ticking on the 18-month window ... on the city's wireless Internet service. , ,After months of ... EarthLink and Cellnet , Mayor Tom Barrett ... access to city facilities to build a $20 million "Wi-Fi" ...
Cached Biology Technology:Doyle, WARF announce partnership to lure stem cell companies 2Doyle, WARF announce partnership to lure stem cell companies 3Medical College to build $6M transplant database 2Milwaukee could be wireless in 18 months 2
(Date:10/16/2014)... October 16, 2014 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... technologies including Wocket™, the Smart Wallet, at the 13 ... is a leading global conference on the intersection of ... Mark Anderson , founder and publisher of the ...
(Date:10/15/2014)... risk from strains of influenza virus increases with the ... become complacent that the most substantial threats have been ... pandemics arise when a new virus strain – against ... spreads in the human population. There have been five ... of which – the 1918 Spanish Flu – cost ...
(Date:10/15/2014)... Johannes Gutenberg University Mainz (JGU) as a full ... to maintain a significant nationwide standing in the ... of Johannes Gutenberg University Mainz as a full ... the national and international competition for the best ... can be proud that Mainz University has been ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... Calif., May 9, 2012 Human cells are thought to ... that help determine which genes are turned on or off ... normal cellular function, but they can also contribute to human ... promote cell survival. But to better understand how miRNAs influence ...
... to understand how the aging process affects the brain ... older adults. "Everybody ages differently. By looking at ... health, we begin to understand that preventable factors may ... University psychology doctoral student Andrew Bender, lead author of ...
... May 9, 2012 (Bronx, NY) Researchers at ... University have discovered a molecule that inhibits the action ... in the growth, maintenance and repair of reproductive tissues ... The molecule, discovered in animal studies, could lead to ...
Cached Biology News:It's a trap! New laboratory technique captures microRNA targets 2WSU researchers say genes and vascular risk modify effects of aging on brain and cognition 2WSU researchers say genes and vascular risk modify effects of aging on brain and cognition 3Molecule found that inhibits estrogen, key risk factor for endometrial and breast cancers 2
...
... This CLS number is a ... match Cornings product number. If showing ... the old Sigma-Aldrich number (R4276) or ... Material: cap polystyrene (expanded surface, easy ...
... Custom Peptide Services offer a full range ... research needs. Services include: Peptide synthesis, ... Peptide synthesis, purified product (70-95% pure) ... amidation, biotinylation, fluorescein, myristylation, phosphorylation, and rhodamine) ...
... ELISPOT (enzyme-lined immunospot) Kit analyzes interferon gamma ... A spot forms at the site where ... using a dissection microscope or automated ELISPOT ... of cells added to the microplate. This ...
Biology Products: